These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 32630096)

  • 1. T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road.
    Crowther MD; Svane IM; Met Ö
    Cells; 2020 Jun; 9(7):. PubMed ID: 32630096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy.
    Sharma P; Kranz DM
    Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
    Chandran SS; Klebanoff CA
    Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
    Rath JA; Arber C
    Cells; 2020 Jun; 9(6):. PubMed ID: 32570906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
    Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
    J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The promise and potential pitfalls of chimeric antigen receptors.
    Sadelain M; Brentjens R; Rivière I
    Curr Opin Immunol; 2009 Apr; 21(2):215-23. PubMed ID: 19327974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
    Harris DT; Kranz DM
    Trends Pharmacol Sci; 2016 Mar; 37(3):220-230. PubMed ID: 26705086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
    Chen L; Qiao D; Wang J; Tian G; Wang M
    Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
    Yang QY; Yang JD; Wang YS
    Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered T cells: the promise and challenges of cancer immunotherapy.
    Fesnak AD; June CH; Levine BL
    Nat Rev Cancer; 2016 Aug; 16(9):566-81. PubMed ID: 27550819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies.
    Abbott RC; Cross RS; Jenkins MR
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31947597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy.
    Hardaway JC; Prince E; Arepally A; Katz SC
    J Vasc Interv Radiol; 2018 Jul; 29(7):1017-1021.e1. PubMed ID: 29935783
    [No Abstract]   [Full Text] [Related]  

  • 14. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy.
    Hinrichs CS
    Clin Cancer Res; 2016 Apr; 22(7):1559-64. PubMed ID: 27037253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T Cell Receptor Engineered Lymphocytes for Cancer Therapy.
    Rollins MR; Spartz EJ; Stromnes IM
    Curr Protoc Immunol; 2020 Jun; 129(1):e97. PubMed ID: 32432843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of RNA Interference with TCR Transfer to Enhance Safety and Efficiency.
    Casey NP; Kyte JA; Fujiwara H
    Methods Mol Biol; 2020; 2115():327-349. PubMed ID: 32006409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
    Jindal V; Arora E; Gupta S
    Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.